News

Bellerophon‘s positive top-line results from its Phase 2 trial testing INOpulse as a potential therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) will be presented at an upcoming conference, the company announced. Results of the trial, which were initially announced in September 2017,…

Horizon 2020, the European Union’s prestigious research and innovation program, recently awarded ATXA Therapeutics €2.5 million ($2.91 million) to support the development of ATXA’s lead therapy candidate NTP42 and help get it to market quicker as a treatment for pulmonary arterial hypertension (PAH). The ATXA research project was…

The non-profit Team PHenomenal Hope is helping Puerto Ricans with pulmonary hypertension (PH) during the ongoing power outage crisis by providing portable solar panels and battery packs. The power outage was caused by Hurricane Maria, in September 2017, which inflicted significant damage to the island. Recovery wasn’t easy…

The European Union isn’t doing enough to protect the 30 million or so people with rare diseases who live in its 28 member countries, officials meeting last week in Vienna said. More than 900 people from 58 nations attended the 9th European Conference on Rare Diseases & Orphan Drugs (ECRD),…

The National Organization for Rare Disorders (NORD) will celebrate the 35th anniversary of both the 1983 Orphan Drug Act and NORD’s founding at a dinner tonight in Washington, D.C. The 2018 Rare Impact Awards, to be held at the Andrew W. Mellon Auditorium, will be webcast via Facebook for those…

Clinical features of sarcoidosis-associated pulmonary hypertension are similar across patients in the U.S., Europe and Middle East, but treatment is more likely to be given to patients outside the United States, a study reports. These findings were drawn from data on 176 sarcoidosis-associated pulmonary hypertension (SAPH) patients enrolled in a…

Scottish patients with pulmonary arterial hypertension (PAH) can now be treated with Actelion‘s Uptravi (selexipag) through the country’s National Health System (NHS) after a positive recommendation from the Scottish Medicines Consortium (SMC). However, the use of this therapy will be restricted to adult patients in WHO functional…

Reata Pharmaceuticals is currently recruiting participants for its Phase 3 CATALYST trial assessing the effectiveness of bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). After analysis of the Phase 2 LARIAT study (NCT02036970) results in pulmonary hypertension (PH) and interim data of the first 100…

A project investigating the role of a special protein called PFKFB3 in pulmonary hypertension (PH) has been awarded a $2.2 million grant from the National Heart, Lung and Blood Institute. PFKFB3 is a potential new therapeutic target for early stages of PH. PFKFB3 is an enzyme involved in the…

Bellerophon Therapeutics announced that is moving forward with a planned Phase 2b trial that will investigate INOpulse as a therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), following an agreement with the U.S. Food and Drug Administration regarding the study’s design. INOpulse therapy is based on…

Age, ischemic heart disease, and kidney dysfunction are important predictors of outcomes in patients with idiopathic pulmonary arterial hypertension (IPAH), a Swedish study shows. The research, “Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension,” was published recently in the European Respiratory Journal.

A gene called FoxM1 was seen to be an important regulator of the vascular remodeling process involved in pulmonary hypertension.  It triggers the proliferation of smooth muscle cells in the lung’s blood vessels, which in turn promotes the thickening of artery walls and elevated arterial blood pressure. Inhibiting or blocking FoxM1 activity…